Romain A.
- Country
- France
- Department
- Service d'Hépato-Gasroentérologie et Transplantation
Research Overview
- Long-term Safety, Tolerability, and Efficacy of Balinatunfib in Adults with Crohn's Disease or Ulcerative Colitis: A Multicenter Extension Study
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
Data & Insights
Has run more than one trial at 413 of 628 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating inflammatory bowel diseases, with particular emphasis on ulcerative colitis and Crohn's disease. Their research encompasses both moderate and severe disease manifestations.
- Novel Therapeutic Approaches
- Long-term Disease Management
- Treatment Response Evaluation
Advanced Treatment Modalities
Their expertise extends to investigating targeted therapies and biological treatments for inflammatory bowel conditions. The investigator focuses on evaluating therapeutic options for patients with inadequate response to conventional treatments.
- Maintenance Therapy Development
- Treatment Optimization Strategies
- Therapeutic Drug Monitoring
Specialized Disease Management
The investigator has particular interest in treating complex manifestations including perianal Crohn's disease and managing postoperative recurrence. Their work includes evaluation of endoscopic improvement and clinical remission.
- Fistula Treatment
- Disease Activity Assessment
- Innovative Treatment Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.